$IQV

BOUSBIB ARI sold $26.1M of IQV

BOUSBIB ARI (See Remarks) sold 106,279 shares of IQVIA HOLDINGS INC. (IQV) at an average of $245.51 ($244.78–$247.10, $26.09M total) across 4 trades on 2026-07-29.

Original reporting
SEC EDGAR · BOUSBIB ARI
Published Jul 31, 2026, 9:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 31, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IQV
Neutral
low confidence
Mentioned
$IQV
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IQVNeutralLow
01

Why it matters

The newest fact is the disclosed sale size ($26.09M) and the trade price range ($244.78 to $247.10) by an officer/director on 2026-07-29.

02

Market read

Traders may monitor for follow-on insider activity or interpret the sale as mild negative sentiment, but there is no new operating or financial guidance in the filing.

03

What to watch

The text does not state whether the sale was part of a broader program, tax event, or diversification plan, and it provides no context on prior insider activity.

Relevance 7/10Novelty 5/10Timing: filed 2026-07-31 after trades dated 2026-07-29

Background

This is an SEC Form 4 insider transaction disclosure for IQVIA Holdings Inc.

Company-level read

Ticker impact

$IQVNeutralLow confidence
Context

IQVIA Form 4 shows officer/director BOUSBIB ARI sold $26.1M of IQV shares in open-market transactions at $244.78 to $247.10 on 2026-07-29.

Expected impact

Likely limited, short-lived sentiment impact unless follow-on selling or new fundamentals emerge.

Evidence & confidence

The filing is a routine Form 4 insider sale with no 10b5-1 plan stated and no accompanying company-specific operational update in the text.

Market effects

No sector-wide read-through is provided; this is company-specific insider activity only.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity or diversification, so the signal may be overstated without evidence of distress or a 10b5-1 plan.

Key entities

  • IQVIA HOLDINGS INC.

    Subject of the Form 4 insider sale disclosure.

  • BOUSBIB ARI

    Officer and director who sold 106,279 shares across four trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IQVMed

Stifel raises IQVIA stock price target on improving market backdrop

Stifel raised its price target for IQVIA (NYSE:IQV) to $303 from $276, citing an improving market backdrop and strong company performance. The stock is near its 52-week high and has surged 48.72% over the past six months. Multiple analysts have raised their price targets and maintained buy ratings, highlighting IQVIA's growth prospects and strong data infrastructure.

$IQVHighAI 8/10

IQVIA Holdings (IQV) Prices $2b In Senior Notes, Is The Stock Still Undervalued?

IQVIA Holdings (IQV) priced a $2b senior notes offering due 2034. The company's share price has surged 58.8% in 90 days, with a 1-year return of 42.3%. Analysts estimate a fair value of $275.17, suggesting a modest undervaluation. However, risks include contract pricing pressure and higher leverage. The company's R&D solutions backlog and pipeline growth indicate sustained demand.

$IQVMed

Learn Why The Bull Case For IQVIA (IQV) Could Change Following AI Trial Platform Launch

IQVIA Holdings priced a $2.0b senior notes offering due 2034 to refinance debt and cover costs. The company launched IQVIA Predictive Clinical Development, an AI-driven platform aimed at accelerating clinical trials. Analysts project revenues of $20.4b and earnings of $2.0b by 2029, but debt remains a key risk. The AI platform could enhance growth and defend pricing power, though competition from in-house pharma tools is a concern.